Sumitomo Mitsui Trust Group Inc. Has $28.81 Million Holdings in United Therapeutics Corporation $UTHR

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,248 shares of the biotechnology company’s stock after purchasing an additional 2,521 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.22% of United Therapeutics worth $28,806,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. HB Wealth Management LLC grew its position in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 35 shares in the last quarter. Hohimer Wealth Management LLC lifted its holdings in shares of United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock worth $3,900,000 after acquiring an additional 37 shares during the period. Park Avenue Securities LLC lifted its holdings in shares of United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after acquiring an additional 39 shares during the period. Applied Finance Capital Management LLC lifted its holdings in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock worth $349,000 after acquiring an additional 40 shares during the period. Finally, Headlands Technologies LLC lifted its holdings in shares of United Therapeutics by 1.5% during the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock worth $828,000 after acquiring an additional 40 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on UTHR. Royal Bank Of Canada began coverage on shares of United Therapeutics in a report on Friday, September 26th. They set an “outperform” rating and a $569.00 price target for the company. Morgan Stanley upped their price target on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. UBS Group upped their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Jefferies Financial Group upped their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, Wells Fargo & Company began coverage on shares of United Therapeutics in a report on Monday, October 20th. They set an “underweight” rating and a $414.00 price target for the company. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $461.62.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The SEC filing for this sale provides additional information. In the last three months, insiders sold 349,435 shares of company stock valued at $144,451,272. 10.30% of the stock is owned by insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $415.34 on Wednesday. The company has a market cap of $18.74 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 4.59 and a beta of 0.66. The firm has a 50 day simple moving average of $401.57 and a 200 day simple moving average of $334.83. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $459.48.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the company earned $5.85 EPS. As a group, analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.